
Optomed Q3 - Solid quarter from both the software and devices segment

Redeye provides an update in relation to Optomed's Q3 2023 report. The report came in better than expected, with sales of EUR4.2m (EUR3.7m) and a solid positive cash flow from operating activities. Furthermore, we assume that the additional data has not been sent in yet to the FDA. We now expect a potential FDA approval in early 2024 and view this as a major trigger for the share. Moreover, we only make minor estimate changes; however, we increase our WACC, which renders in an updated fair value range, including a new base case of EUR7.5 (8).

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Optomed Q3 - Solid quarter from both the software and devices segment](#)